Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.

Pharmeuropa bio & scientific notes·2024
Same author

Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Factor VII activating protease.

Hamostaseologie·2018
Same author

Factor VII-activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.

The European journal of neuroscience·2015
Same author

The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity.

Thrombosis research·2012

Related Experiment Video

Updated: Jun 1, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor VII activating protease. Single nucleotide polymorphisms light the way.

S M Kanse1, M Etscheid

  • 1Department of Medicine, Justus-Liebig-University, Friedrichstraße 24, 35392 Giessen, Germany. sandip.kanse@biochemie.med.uni-giessen.de

Hamostaseologie
|June 10, 2011
PubMed
Summary

Factor VII activating protease (FSAP) influences blood clotting and inflammation. Genetic variations (SNPs) in the FSAP gene are linked to diseases like stroke and thrombosis, suggesting its critical role in hemostasis.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Biochemistry
  • Hematology
  • Genetics

Background:

  • Factor VII activating protease (FSAP) is a serine protease homologous to fibrinolytic enzymes.
  • In vitro studies suggest FSAP regulates coagulation and fibrinolysis by activating FVII and pro-urokinase plasminogen activator (uPA).
  • FSAP interacts with growth factors and protease-activated receptors (PARs), implicating it in vascular remodeling and inflammation.

Purpose of the Study:

  • To clarify the role of FSAP in hemostasis, vascular remodeling, and inflammation.
  • To investigate the association between FSAP gene single nucleotide polymorphisms (SNPs) and various diseases.

Main Methods:

  • Review of in vitro studies on FSAP's enzymatic activity.
  • Analysis of studies linking FSAP gene (HABP2) SNPs to disease phenotypes.
  • Focus on the G534E SNP and its impact on FSAP proteolytic activity.

Main Results:

  • The precise role of FSAP in human hemostasis remains unclear due to limited in vivo data.
  • FSAP gene SNPs, including G534E (associated with reduced activity), are linked to carotid stenosis, stroke, thrombosis, and plaque calcification.
  • These associations suggest FSAP's involvement in hemostasis and fibroproliferative inflammatory processes.

Conclusions:

  • FSAP plays a significant role in regulating hemostasis and inflammatory processes.
  • FSAP gene variations are associated with increased risk for vascular and thrombotic diseases.
  • Further in vivo research is needed to fully elucidate FSAP's function in health and disease.